CBL0137
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for CBL0137, covering 2025-04-04 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma [Phase 1, Phase 2]